MARKET

STOK

STOK

Stoke Therapeutics
NASDAQ
36.41
+0.86
+2.42%
After Hours: 36.41 0 0.00% 17:21 02/27 EST
OPEN
35.20
PREV CLOSE
35.55
HIGH
36.61
LOW
34.66
VOLUME
653.55K
TURNOVER
--
52 WEEK HIGH
38.69
52 WEEK LOW
5.35
MARKET CAP
2.08B
P/E (TTM)
55.17
1D
5D
1M
3M
1Y
5Y
1D
Stoke Therapeutics CEO Ian F. Smith to Present at TD Cowen 46th Annual Health Care Conference
Reuters · 3d ago
Forecasting The Future: 5 Analyst Projections For Stoke Therapeutics
Benzinga · 3d ago
Stoke Therapeutics Initiated at Outperform by Wolfe Research
Dow Jones · 3d ago
Stoke Therapeutics Price Target Announced at $40.00/Share by Wolfe Research
Dow Jones · 3d ago
Stoke Therapeutics (STOK) Is Up 13.5% After First Patient Dosed In STK-002 OSPREY Trial
Simply Wall St · 3d ago
Stoke Therapeutics initiated with an Outperform at Wolfe Research
TipRanks · 4d ago
Weekly Report: what happened at STOK last week (0216-0220)?
Weekly Report · 4d ago
Stoke Therapeutics participates in a conf call hosted by Cantor Fitzgerald
TipRanks · 02/20 14:26
More
About STOK
Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-002), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.

Webull offers Stoke Therapeutics Inc stock information, including NASDAQ: STOK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STOK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading STOK stock methods without spending real money on the virtual paper trading platform.